Genmab
Clinical Trials
246
Trial Phases
4 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (191 trials with phase data)• Click on a phase to view related trials
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Drug: Investigator's Choice Chemotherapy
- First Posted Date
- 2025-11-10
- Last Posted Date
- 2025-11-10
- Lead Sponsor
- Genmab
- Target Recruit Count
- 72
- Registration Number
- NCT07226752
- Locations
- 🇨🇳
Affiliated Hospital of Hebei University, Baoding, China
🇨🇳Beijing Cancer Hospital, Beijing, China
🇨🇳Beijing Tongren Hospital, Capital Medical University, Beijing, China
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
- Conditions
- Ovarian CancerPlatinum-sensitive Ovarian CancerPSOC
- Interventions
- First Posted Date
- 2025-11-06
- Last Posted Date
- 2025-11-14
- Lead Sponsor
- Genmab
- Target Recruit Count
- 528
- Registration Number
- NCT07225270
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- Conditions
- Endometrial CancerRecurrent or Progressive Endometrial Cancer
- Interventions
- Drug: IC
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-11-12
- Lead Sponsor
- Genmab
- Target Recruit Count
- 544
- Registration Number
- NCT07166094
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
- Conditions
- Cutaneous MelanomaRelapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)Metastatic Cutaneous Melanoma (Stage IV)
- Interventions
- First Posted Date
- 2025-05-22
- Last Posted Date
- 2025-11-04
- Lead Sponsor
- Genmab
- Target Recruit Count
- 90
- Registration Number
- NCT06984328
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇵🇷Pan American Center for Oncology Trials, LLC, San Juan, Puerto Rico
A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Genmab
- Target Recruit Count
- 3
- Registration Number
- NCT06771921
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇪🇸NEXT Oncology Madrid, Madrid, Spain
🇩🇰Righshospitalet (Copenhagen University Hospital), Copenhagen, Denmark
- Prev
- 1
- 2
- 3
- 4
- 5
- 12
- Next
News
FDA Approves AbbVie and Genmab's Epkinly for Relapsed or Refractory Follicular Lymphoma
AbbVie and Genmab have received FDA approval for Epkinly as a treatment option for patients with relapsed or refractory follicular lymphoma.
FDA Approves First Bispecific Antibody Combination for Relapsed/Refractory Follicular Lymphoma
The FDA has approved epcoritamab (Epkinly) in combination with rituximab and lenalidomide as the first bispecific antibody combination therapy for relapsed or refractory follicular lymphoma patients.
Medicxi Closes €500M Fund V to Accelerate Asset-Centric Biotech Investments
Medicxi successfully raised €500 million ($581 million) for its sixth fund, demonstrating strong investor confidence in its asset-centric investment approach.
Day One Biopharmaceuticals Acquires Mersana Therapeutics for $129M, Targeting Rare Cancer Treatment
Day One Biopharmaceuticals announced the acquisition of Mersana Therapeutics for $129 million upfront, with potential additional payments of $156 million tied to development milestones.
Genmab Reports Strong Q3 2025 Results with Key Pipeline Advances and $8 Billion Merus Acquisition
Genmab achieved 21% revenue growth to $2.66 billion in the first nine months of 2025, driven primarily by increased DARZALEX and Kesimpta royalties.
Five Major FDA Decisions Expected in November 2025 Across Cancer, Rare Disease, and Genetic Disorders
The FDA is set to make five significant regulatory decisions in November 2025, including approvals for treatments targeting rare genetic disorders, multiple cancer types, and kidney disease.
Abivax Phase III Success Triggers 850% Stock Surge, Reignites European Biotech Rally
Abivax shares soared over 850% following positive Phase III data in ulcerative colitis, creating an "Abivax effect" that has reshaped market dynamics and reignited investor confidence in European biotech.
CD40-Targeted Therapies Advance Toward First Approval by 2027 with Over 35 Candidates in Clinical Development
Over 35 CD40-targeted therapies are currently in clinical trials, with the first approval expected by 2027 according to new market research.
Lundbeck Advances Innovative Phase 3 Trial Design for Amlenetug in Multiple System Atrophy
Lundbeck will present details of its Phase 3 MASCOT trial for amlenetug, a first-in-class monoclonal antibody targeting α-synuclein aggregation in Multiple System Atrophy patients.
Biopharma M&A Activity Surges in Q3 2025 with $55.7 Billion in Acquisitions
The biopharmaceutical sector experienced a significant surge in high-value acquisitions during Q3 2025, with four of the year's five largest deals occurring in the past four months.